Semax & Selank vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Semax & Selank
A nootropic combination pairing two Russian-developed peptides for cognitive enhancement. Semax provides stimulating focus and neuroprotection while Selank offers anxiolytic and mood-stabilizing effects, creating a balanced cognitive enhancement stack.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | Semax & Selank | Retatrutide |
|---|---|---|
| Mechanism | Semax enhances BDNF expression and modulates dopamine and serotonin systems for improved focus, memory, and neuroprotection. Selank affects BDNF and GABA systems, providing anxiolytic effects and immune modulation. Together they support cognitive function while managing stress and anxiety. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Semax: 200-600mcg intranasally 2-3 times daily. Selank: 250-500mcg intranasally 2-3 times daily. Can be used together or alternated based on needs. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Primarily administered intranasally for rapid brain uptake. N-Acetyl versions (NA-Semax, NA-Selank) offer enhanced stability and potency. Can also be injected subcutaneously. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Semax may cause mild irritability or hair shedding. Selank may cause mild fatigue or nasal irritation. Both are generally well-tolerated. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |